Kenichiro Kodama
Hiroshima, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
Journal: BMC gastroenterology
Published: November 29, 2022
Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma.
Journal: Internal medicine (Tokyo, Japan)
Published: November 03, 2022
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Journal: Liver cancer
Published: April 28, 2022
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.
Journal: Cancers
Published: December 12, 2021
Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene.
Journal: Case reports in gastroenterology
Published: December 06, 2021
Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study.
Journal: BMC gastroenterology
Published: December 06, 2021
The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.
Journal: PloS one
Published: November 04, 2021
Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
Journal: Journal of gastroenterology
Published: October 27, 2021
Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Journal: Liver cancer
Published: September 16, 2021
Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
Journal: Medicine
Published: July 24, 2021
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice.
Journal: Cancers
Published: July 02, 2021
Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib.
Journal: Journal of experimental & clinical cancer research : CR
Published: April 19, 2021
Last Updated: 09/26/2026